Pictet North America Advisors’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.73M | Buy |
7,280
+88
| +1% | +$89.9K | 0.77% | 40 |
|
|
2026
Q1 | $6.61M | Buy |
7,192
+34
| +0.5% | +$34.5K | 0.66% | 43 |
|
|
2025
Q4 | $7.69M | Buy |
7,158
+17
| +0.2% | +$16.3K | 0.73% | 39 |
|
|
2025
Q3 | $5.45M | Hold |
7,141
| – | – | 0.51% | 45 |
|
|
2025
Q2 | $5.57M | Buy |
7,141
+90
| +1% | +$69.9K | 0.56% | 45 |
|
|
2025
Q1 | $5.82M | Buy |
7,051
+5
| +0.1% | +$4.16K | 0.58% | 44 |
|
|
2024
Q4 | $5.44M | Hold |
7,046
| – | – | 0.52% | 53 |
|
|
2024
Q3 | $6.24M | Buy |
7,046
+13
| +0.2% | +$11.7K | 0.62% | 44 |
|
|
2024
Q2 | $6.37M | Buy |
7,033
+8
| +0.1% | +$6.4K | 0.69% | 44 |
|
|
2024
Q1 | $5.47M | Buy |
7,025
+3,010
| +75% | +$2.14M | 0.61% | 37 |
|
|
2023
Q4 | $2.34M | Buy |
4,015
+15
| +0.4% | +$8.76K | 0.3% | 61 |
|
|
2023
Q3 | $2.15M | Hold |
4,000
| – | – | 0.31% | 62 |
|
|
2023
Q2 | $1.88M | Hold |
4,000
| – | – | 0.26% | 65 |
|
|
2023
Q1 | $1.37M | Hold |
4,000
| – | – | 0.22% | 68 |
|
|
2022
Q4 | $1.46M | Hold |
4,000
| – | – | 0.25% | 57 |
|
|
2022
Q3 | $1.29M | Hold |
4,000
| – | – | 0.21% | 67 |
|
|
2022
Q2 | $1.3M | Hold |
4,000
| – | – | 0.17% | 72 |
|
|
2022
Q1 | $1.15M | Hold |
4,000
| – | – | 0.13% | 74 |
|
|
2021
Q4 | $1.1M | Hold |
4,000
| – | – | 0.11% | 76 |
|
|
2021
Q3 | $924K | Hold |
4,000
| – | – | 0.09% | 78 |
|
|
2021
Q2 | $918K | Hold |
4,000
| – | – | 0.09% | 82 |
|
|
2021
Q1 | $747K | Hold |
4,000
| – | – | 0.09% | 82 |
|
|
2020
Q4 | $675K | Sell |
4,000
-900
| -18% | -$134K | 0.09% | 92 |
|
|
2020
Q3 | $725K | Hold |
4,900
| – | – | 0.1% | 83 |
|
|
2020
Q2 | $804K | Hold |
4,900
| – | – | 0.12% | 84 |
|
|
2020
Q1 | $680K | Hold |
4,900
| – | – | 0.12% | 91 |
|
|
2019
Q4 | $644K | Hold |
4,900
| – | – | 0.08% | 103 |
|
|
2019
Q3 | $548K | Hold |
4,900
| – | – | 0.07% | 109 |
|
|
2019
Q2 | $543K | Hold |
4,900
| – | – | 0.08% | 107 |
|
|
2019
Q1 | $636K | Hold |
4,900
| – | – | 0.1% | 102 |
|
|
2018
Q4 | $567K | Hold |
4,900
| – | – | 0.05% | 107 |
|
|
2018
Q3 | $526K | Buy |
+4,900
| New | +$490K | 0.07% | 119 |
|
|
2017
Q2 | – | Sell |
-2,818
| Closed | -$237K | – | 136 |
|
|
2017
Q1 | $237K | Sell |
2,818
-90,084
| -97% | -$7.22M | 0.04% | 122 |
|
|
2016
Q4 | $6.83M | Sell |
92,902
-16,962
| -15% | -$1.26M | 1.5% | 21 |
|
|
2016
Q3 | $8.82M | Buy |
+109,864
| New | +$8.79M | 2.1% | 16 |
|
Other funds holding LLY
SC
ONB
GIM
Pictet North America Advisors's LLY Position: Q2 2026 in Review
Pictet North America Advisors increased its Eli Lilly (LLY) stake by 1.2% in Q2 2026, buying an estimated $89.9K and bringing the position to 7,280 shares worth $8.73M. The position accounts for 0.77% of the portfolio, ranked #40.
Pictet North America Advisors first reported a position in LLY in Q3 2016 and has held it in 35 quarters since. The position peaked at $8.82M in Q3 2016. 1,652 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Pictet North America Advisors held 7,280 shares of Eli Lilly worth $8.73M as of Q2 2026.
- Pictet North America Advisors bought 88 Eli Lilly shares in Q2 2026, an estimated $89.9K.
- Eli Lilly made up 0.77% of Pictet North America Advisors's portfolio in Q2 2026, its #40 holding.
- Pictet North America Advisors first reported a position in Eli Lilly in Q3 2016 and has held it in 35 quarters since.
- Pictet North America Advisors's Eli Lilly position peaked at $8.82M in Q3 2016.
- 1,652 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Pictet North America Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.